DUBLIN, June 2, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market"  report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO )

The hematological cancers market is forecast to rise from a value of $30.7 billion in 2015 to $70.1 billion in 2022, at a CAGR of 12.5% 

Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating lymphomas are more prevalent than leukemias or myeloma. 

Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent. 

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments were based on the growing understanding of the signaling pathways involved in disease pathogenesis. Notable examples include the approval of rituximab in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin's lymphoma. 

Overall, there are 1,207 products in active development in the hematological cancer therapy area. The indications included in this disease cluster are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development. 

Hematological cancer has more active pipeline products than the respiratory and cardiovascular therapy areas, which indicates how active this disease cluster is in terms of product development. 

Scope 

The hematological cancers market is characterized by commercially successful therapies. 
- Which classes of drug dominate the market? 
- What additional benefits have newly approved therapies brought to the market? 
- How do the leading marketed therapies compare clinically? 

The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents. 
- Which molecular targets appear most frequently in the pipeline? 
- What are the commercial prospects for the most promising late-stage pipeline products? 

Hematological cancers clinical trials have an overall attrition rate of 70.3%. 
- What are the failure rates at individual Phases of clinical development? 
- How do leukemia, lymphoma and myeloma compare in terms of clinical trial failure rate? 

The hematological cancers market is forecast to rise from a value of $30.7 billion in 2015 to $70.1 billion in 2022, at a CAGR of 12.5%. 
- How much of a role will disease prevalence and new product approvals play in market growth? 
- Will generic competition have a significant impact on the market over the forecast period? 

Big pharma hold a notable presence in the market. 
- What are the leading companies in terms of market share? 
- Which companies are forecast to experience the greatest growth in market share? 
- What are the drivers of growth for key companies in the market? 
- How dependent are the key companies on this disease cluster for revenue? 
- Which companies rely heavily on this disease cluster for revenue? 

Companies Mentioned 

- AbbVie/Pharmacyclics 
- Celgene 
- Johnson & Johnson 
- Karyopharm Therapeutics 
- Kite Pharma 
- Novartis 

For more information visit http://www.researchandmarkets.com/research/nlmt3c/global

Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets